MX2023014565A - Tratamiento conjunto para tratamiento contra el cancer. - Google Patents

Tratamiento conjunto para tratamiento contra el cancer.

Info

Publication number
MX2023014565A
MX2023014565A MX2023014565A MX2023014565A MX2023014565A MX 2023014565 A MX2023014565 A MX 2023014565A MX 2023014565 A MX2023014565 A MX 2023014565A MX 2023014565 A MX2023014565 A MX 2023014565A MX 2023014565 A MX2023014565 A MX 2023014565A
Authority
MX
Mexico
Prior art keywords
combination therapy
cancer treatment
cancer
inhibitor
directed
Prior art date
Application number
MX2023014565A
Other languages
English (en)
Inventor
Juergen Wichmann
Hiroshi Tanaka
Thomas Friess
Frank Herting
Piergiorgio Francesco Tommaso Pettazzoni
Jan Eckmann
Yusuke Ide
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2023014565A publication Critical patent/MX2023014565A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al tratamiento conjunto de cáncer con un inhibidor de BRAF y un inhibidor de MEK, así como a usos y composiciones farmacéuticas de estos.
MX2023014565A 2021-06-09 2022-06-07 Tratamiento conjunto para tratamiento contra el cancer. MX2023014565A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21178403 2021-06-09
PCT/EP2022/065393 WO2022258612A1 (en) 2021-06-09 2022-06-07 Combination therapy for cancer treatment

Publications (1)

Publication Number Publication Date
MX2023014565A true MX2023014565A (es) 2024-02-08

Family

ID=76355323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014565A MX2023014565A (es) 2021-06-09 2022-06-07 Tratamiento conjunto para tratamiento contra el cancer.

Country Status (11)

Country Link
US (1) US20240139192A1 (es)
EP (1) EP4351577A1 (es)
KR (2) KR20240008410A (es)
CN (1) CN117642166A (es)
AU (1) AU2022288118A1 (es)
BR (1) BR112023025916A2 (es)
CA (1) CA3222549A1 (es)
IL (1) IL307964A (es)
MX (1) MX2023014565A (es)
TW (1) TW202313046A (es)
WO (1) WO2022258612A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240105382A (ko) * 2021-11-04 2024-07-05 에프. 호프만-라 로슈 아게 암 치료를 위한 퀴나졸리논 화합물의 신규한 용도
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275102B1 (en) 2002-03-13 2015-07-29 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP3094627B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3094629B1 (en) 2014-01-17 2018-08-22 Novartis AG 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
TW201930292A (zh) 2017-10-12 2019-08-01 美商銳新醫藥公司 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
WO2021116055A1 (en) * 2019-12-10 2021-06-17 F. Hoffmann-La Roche Ag New methylquinazolinone derivatives
PE20231094A1 (es) * 2020-07-22 2023-07-18 Chugai Pharmaceutical Co Ltd Composicion que contiene un derivado de arilamida

Also Published As

Publication number Publication date
WO2022258612A1 (en) 2022-12-15
IL307964A (en) 2023-12-01
AU2022288118A1 (en) 2023-11-30
CA3222549A1 (en) 2022-12-15
CN117642166A (zh) 2024-03-01
BR112023025916A2 (pt) 2024-02-27
EP4351577A1 (en) 2024-04-17
US20240139192A1 (en) 2024-05-02
TW202313046A (zh) 2023-04-01
KR20240005899A (ko) 2024-01-12
KR20240008410A (ko) 2024-01-18

Similar Documents

Publication Publication Date Title
NZ756754A (en) Combination therapy for the treatment or prevention of tumours
JOP20220008A1 (ar) مثبطات parp1
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
EA202190630A1 (ru) Способы комбинированной терапии
MX2023014565A (es) Tratamiento conjunto para tratamiento contra el cancer.
CR20220169A (es) Heterociclos bicíclicos como inhibidores de fgfr
MX2022001004A (es) Inhibidores de enzimas.
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
EA202190749A1 (ru) Способы комбинированной терапии
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2022012471A (es) Combinaciones de inhibidores de menina e inhibidores de cyp3a4 y métodos de uso de las mismas.
MX2021001612A (es) Compuestos utiles en terapia del vih.
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022006176A (es) Terapia combinada que comprende un inhibidor de alk2 y un inhibidor de jak2.
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2022000811A (es) Inhibidores de enzimas.
MX2021012705A (es) Compuestos con actividad antitumoral contra las celulas cancerosas que portan mutaciones en el receptor del factor de crecimiento epidermico (egfr) resistentes al inhibidor de la tirosina quinasa.